[1] 张希, 刘萍. 骨性关节炎所致慢性持续性疼痛的发病机制 [J]. 中国骨质疏松杂志,2017,23(2):248-255.
[2] MARTEL-PELLETIER J, BARR A J, CICUTTINI FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.
[3] 贺娟娟, 颜春鲁, 安方玉, 等. 炎症因子与炎症因子相关信号通路在膝骨关节炎中的调控机制研究进展[J].中国临床药理学杂志, 2019,35(12):1308-1311.
[4] LARKIN J, LOHR TA, ELEFANTE L, et al.Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015;23(8):1254-1266.
[5] WANG T, HE C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50.
[6] CHEN D, LU D, LIU H, et al. Pharmacological blockade of PCAF ameliorates osteoarthritis development via dual inhibition of TNF-α-driven inflammation and ER stress. EBioMedicine. 2019;50:395-407.
[7] LóPEZ-ARMADA MJ, CARAMéS B, LIRES-DEáN M, et al. Cytokines, tumor necrosis factor-alpha and interleukin-1beta, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteoarthritis Cartilage. 2006;14(7):660-669.
[8] SHU S, ZHU J, LIU Z, et al. Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease. EBioMedicine. 2018;37:269-280.
[9] LIU-BRYAN R, TERKELTAUB R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015:11(1):35-44.
[10] ZHAO Y, LI Y, QU R, et al. Cortistatin binds to TNF-α receptors and protects against osteoarthritis. EBioMedicine. 2019:41:556-570.
[11] YAMAZAKI H, SO R, MATSUOKA K, et al. Certolizumab pegol for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2019;8(8):Cd012893.
[12] WITTOEK R, CARRON P, LAMBERT B, et al. Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study. Ann Rheum Dis. 2018;77(2):310-311.
[13] 安富荣,崔岚,王勤.自身免疫性疾病的生物治疗新药阿达木单抗[J].中国新药杂志,2010,19(14):1197-1200+1233.
[14] 范晓蕾, 刘中华, 岳涛, 等. 血清TNF-α、IL-1β、IL-6和IL-17表达水平在阿达木单抗治疗活动性类风湿关节炎中的疗效预测作用[J]. 中国医科大学学报,2018,47(6):556-561.
[15] HORNEFF G, SEYGER MMB, ARIKAN D, et al. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease. J Pediatr. 2018;201:166-175.e163.
[16] LIM H, LEE SH, LEE HT, et al. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Int J Mol Sci. 2018; 19(3):768.
[17] OSSENDORFF R, GRAD S, STODDART MJ, et al. Autologous Chondrocyte Implantation in Osteoarthritic Surroundings: TNFalpha and Its Inhibition by Adalimumab in a Knee-Specific Bioreactor. Am J Sports Med. 2018; 46(2):431-440.
[18] MA CH, LV Q, YU YX, et al. Protective effects of tumor necrosis factor-alpha blockade by adalimumab on articular cartilage and subchondral bone in a rat model of osteoarthritis. Braz J Med Biol Res. 2015;48(10):863-870.
[19] MAKSYMOWYCH WP, RUSSELL AS, CHIU P, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther. 2012;14(5):R206.
[20] CHEVALIER X, RAVAUD P, MAHEU E, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2015;74(9):1697-1705.
[21] AITKEN D, LASLETT L L, PAN F, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthritis Cartilage. 2018; 26(7):880-887.
[22] ZHANG Q, LV H, CHEN A, et al. Efficacy of infliximab in a rabbit model of osteoarthritis. Connect Tissue Res. 2012;53(5):355-358.
[23] FIORAVANTI A, FABBRONI M, CERASE A, et al. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int. 2009;29(8):961-965.
[24] SEIDEL M F, WISE B L, LANE N E. Nerve growth factor: an update on the science and therapy. Osteoarthritis Cartilage. 2013;21(9):1223-1228.
[25] DENK F, BENNETT D L, MCMAHON S B. Nerve Growth Factor and Pain Mechanisms. Annu Rev Neurosci. 2017;40:307-325.
[26] SOUSA-VALENTE J, CALVO L, VACCA V, et al. Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthritis Cartilage. 2018;26(1):84-94.
[27] MANTYH PW, KOLTZENBURG M, MENDELL LM, et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189-204.
[28] SCHMELZ M, MANTYH P, MALFAIT AM, et al.Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019;160(10):2210-2220.
[29] KIVITZ AJ, GIMBEL JS, BRAMSON C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154(7):1009-1021.
[30] SPIERINGS EL, FIDELHOLTZ J, WOLFRAM G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154(9):1603-1612.
[31] LANE NE, SCHNITZER TJ, BIRBARA CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010; 363(16):1521-1531.
[32] SCHNITZER TJ, EASTON R, PANG S, et al. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA. 2019;322(1):37-48.
[33] KATZ JN. Tanezumab for Painful Osteoarthritis. JAMA. 2019;322(1): 30-32.
[34] SCHNITZER TJ, EKMAN EF, SPIERINGS EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74(6):1202-1211.
[35] NAGASHIMA H, SUZUKI M, ARAKI S, et al. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405-1412.
[36] CISTERNAS MG, MURPHY L, SACKS JJ, et al. Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population-Based Survey. Arthritis Care Res (Hoboken). 2016;68(5): 574-580.
[37] KELLY KM, SANGA P, ZAKI N, et al. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr Med Res Opin. 2019;35(12): 2117-2127.
[38] SANGA P, KATZ N, POLVEREJAN E, et al. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study. Arthritis Rheumatol. 2017;69(4):763-773.
[39] MAYORGA AJ, WANG S, KELLY KM, et al. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Int J Clin Pract.2016;70(6): 493-505.
[40] BERENBAUM F. Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect? Joint Bone Spine. 2019;86(2): 127-128.
[41] TISEO PJ, KIVITZ AJ, ERVIN JE, et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 2014;155(7):1245-1252.
[42] DAKIN P, DIMARTINO SJ, GAO H, et al. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Arthritis Rheumatol. 2019:71(11):1824-1834.
[43] FENG Z, LI X, LIN J, et al. Oleuropein inhibits the IL-1β-induced expression of inflammatory mediators by suppressing the activation of NF-κB and MAPKs in human osteoarthritis chondrocytes. Food Funct. 2017;8(10):3737-3744.
[44] WOJDASIEWICZ P, PONIATOWSKI ŁA, SZUKIEWICZ D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.
[45] CHEN J, GU YT, XIE JJ, et al. Gastrodin reduces IL-1β-induced apoptosis, inflammation, and matrix catabolism in osteoarthritis chondrocytes and attenuates rat cartilage degeneration in vivo. Biomed Pharmacother. 2018;97:642-651.
[46] KAPOOR M, MARTEL-PELLETIER J, LAJEUNESSE D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33-42.
[47] LEE HJ, LEE SM, MOON YG, et al. Membrane-Free Stem Cell Components Inhibit Interleukin-1alpha-Stimulated Inflammation and Cartilage Degradation in vitro and in vivo: A Rat Model of Osteoarthritis. Int J Mol Sci. 2019;20(19):4869.
[48] CHELESCHI S, CANTARINI L, PASCARELLI N A, et al. Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes. Cytokine.2015;71(2):165-172.
[49] YAMAMOTO K, TROEBERG L, SCILABRA SD, et al. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. FASEB J. 2013;27(2):511-521.
[50] SANTAMARIA S, YAMAMOTO K, BOTKJAER K, et al. Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2). Biochem J. 2015; 471(3):391-401.
[51] YAMAMOTO K, OKANO H, MIYAGAWA W, et al. MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1. Matrix Biol. 2016;56:57-73.
[52] SCILABRA SD, TROEBERG L, YAMAMOTO K, et al. Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1. J Biol Chem. 2013;288(1):332-342.
[53] YAMAMOTO K, OWEN K, PARKER AE, et al. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. J Biol Chem. 2014;289(10): 6462-6474.
[54] YAMAMOTO K, SANTAMARIA S, BOTKJAER KA, et al. Inhibition of Shedding of Low-Density Lipoprotein Receptor-Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis. Arthritis Rheumatol. 2017;69(6):1246-1256.
[55] ZHENG S, HUNTER D J, XU J, et al. Monoclonal antibodies for the treatment of osteoarthritis. Expert Opin Biol Ther. 2016;16(12): 1529-1540.
[56] MALFAIT AM, RITCHIE J, GIL AS, et al. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. Osteoarthritis Cartilage. 2010;18(4): 572-580.
[57] CHIUSAROLI R, VISENTINI M, GALIMBERTI C, et al. Targeting of ADAMTS5’s ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis. Osteoarthritis Cartilage. 2013;21(11):1807-1810.
[58] MILLER RE, TRAN PB, ISHIHARA S, et al. Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 2016;24(2): 299-306.
[59] APTE SS. Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis. Biochem J. 2016;473(1):e1-4.
[60] LEE S, NEMEñO JG, LEE J I. Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration. Tissue Eng Part B Rev. 2016;22(5):341-357.
[61] HAMILTON JL, NAGAO M, LEVINE B R, et al. Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J Bone Miner Res. 2016;31(5):911-924.
[62] LI L, LIU F, HUANG W, et al. Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. Biomed Pharmacother. 2019;118:109357.
[63] NAGAO M, HAMILTON JL, KC R, et al. Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis. Sci Rep. 2017:7(1): 13027.
[64] LI W, LIN J, WANG Z, et al. Bevacizumab tested for treatment of knee osteoarthritis via inhibition of synovial vascular hyperplasia in rabbits. J Orthop Translat. 2019;19:38-46.
[65] LU W, WANG L, YAO J, et al. C5a aggravates dysfunction of the articular cartilage and synovial fluid in rats with knee joint immobilization. Mol Med Rep. 2018;18(2):2110-2116.
[66] NAGAI T, SATO M, KOBAYASHI M, et al. Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis. Arthritis Res Ther. 2014;16(5):427.
[67] LI L, LIU F, HUANG W, et al. Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. Biomed Pharmacother. 2019;118:109357.
[68] COOK AD, POBJOY J, STEIDL S, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14(5):R199.
[69] LEE KM, PRASAD V, ACHUTHAN A, et al. Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice. Osteoarthritis Cartilage. 2020;28(4):486-491.
|